ZURICH May 15 Shares in Swiss pharmaceuticals
company Newron leapt at the start of Tuesday trading
after the company said it had reached a license agreement for
its Parkinson's disease treatment safinamide with Zambon of
The company said it expects to file safinamide globally
after completing Phase III studies in early and advanced
Parkinson's disease patients.
Newron also said Chief Executive Luca Benatti will leave the
company to pursue other, undisclosed opportunities at the end of
Shares were up 49 percent to 5.97 francs by 0715 GMT after
opening more than 60 percent higher.
(Reporting by Martin de Sa'Pinto)